The 46th session of the Jian Shi Structural Heart Academy—“Jie Ban Tong Xing: Practical Course (Animal Experiment)” —was successfully held at the Guorui Heart Innovation and Safety Assessment Institution.
Release time:
2024-03-15 18:23
Keywords:
Technology,Medical
03 Moon 09 On [date], the 46th session of the “Jie Ban Tong Xing Practical Course (Animal Experiment)” organized by Jian Shi Structural Heart Academy, a member enterprise of Jian Shi Medical Technology Group, was successfully held in the conference room and laboratory of Shaanxi Guorui Xin Chuang Medical Technology Co., Ltd.
Professor Yang Jian provided the trainees with a detailed introduction to the apical approach. TAVI Surgical Procedure Guidelines 
Teacher Liu Quan does it. J-Valve Summary of Animal (Pig) Studies on the Characteristics of Transapical Interventional Artificial Bioprosthetic Heart Valves
Experts pose for a group photo with the trainees.
Practical Training on Apical Pouch Suturing
Interventional Device Operation Demonstration
Expert Profile:
Professor Yang Jian
Director of the First Department of Cardiovascular Surgery, Xijing Hospital, Air Force Medical University; Doctoral Supervisor.
American Heart Association Expert Member FAHA ), Fellow of the American College of Cardiology ( FACC );
Recipient of the Shaanxi Province Leading Talent in Science and Technology Innovation for Middle-aged and Young Researchers, Leader of the Shaanxi Province Science and Technology Innovation Team, and recipient of the Shaanxi Province Outstanding Youth Science Fund Project.
Clinically, he excels in minimally invasive transcatheter interventions for various structural heart diseases, including mitral valve and aortic valve disorders, and was honored as a “National Distinguished Physician” in the 4th round of the award. He is also actively involved in the research and development of minimally invasive cardiovascular devices, their clinical translation, and... 3D Has achieved certain accomplishments in multimodal imaging assessment primarily focused on printing;
One after another EUR Heart J 、 JACC Published as first or corresponding author in international journals. SCI Paper More than 50 This section undertakes projects under the National Key R&D Program, the National Natural Science Foundation, and other similar initiatives. 10 Other funds, funding 1000 Over ten thousand yuan;
Received awards including the Second Prize of the National Science and Technology Progress Award and the First Prize of the Chinese Medical Science and Technology Award. Granted national patents. 30 Other items. Chief editor of “Cardiovascular” 3D Printing Technology》、 Cardiovascular 3D printing (English version)》, "Transcatheter Aortic Valve Replacement in…" 3D “Printing Technology—Applications and Practice” and “Guideline Manual for Transcatheter Aortic Valve Implantation,” among others 5 A specialized monograph.
Jiecheng Medical:
China’s original creation, finally completed. TAVR “One Pole”!
Jiecheng Medical to 2009 Founded by cardiac surgeon Zhang Ji, this is a relatively low-profile heart valve company. However, it enjoys a highly regarded reputation in the field of transcatheter heart valve therapy and is often referred to as a domestically produced... TAVR A “leader” in its field and one of the “Four Little Dragons,” its products are also hailed as a “leading force” in global heart valve innovation.
These reviews stem from its core product. J-Valve Precision Positioning Cardiac Valve Implantation System” (abbreviated as J-Valve Valve): This cardiac valve product features 200 Multiple international patents and patent applications, at 2017 Yearly obtained approval from the National Medical Products Administration (NMPA) NMPA )’s approval for market launch is currently the only one to have obtained NMPA An interventional valve product approved for the simultaneous treatment of both severe aortic valve regurgitation (insufficiency) and stenosis.
Jianshi Medical:
Jianshi Medical Technology Group was founded in 2019 Year is an emerging medical technology company.
JianShi is committed to building an open medical technology platform: Through a global innovation network, local R&D and manufacturing capabilities, and continuously enhanced commercialization expertise, JianShi is deeply rooted in the vast Chinese market, providing high-quality medical technology products and services to doctors and patients across China. JianShi Medical... 2022 The acquisition of Suzhou Jiecheng Medical Technology Co., Ltd. was completed this year; the latter is a domestic company specializing in transcatheter aortic valve replacement. Transcatheter Aortic Valve Replacement , later abbreviated as TAVR) A “leader” in the field.
Introduction to Guorui Xinchuang Company:
Shaanxi Guorui Xinchuang Medical Technology Co., Ltd. is an independent, third-party clinical preclinical safety evaluation research institution for medical devices, established on... 2020 Year 06 Yue was registered and established in Kongxin New City. It is currently a comprehensive medical device safety evaluation institution in the northwest region, primarily providing product safety evaluation services to R&D companies of Class II and Class III medical devices. Guorui Xinchuang has already purchased Siemens equipment. DSA Experimental equipment and instruments, including digital subtraction angiography machines, Youwo high-pressure injectors for angiography, Mindray respiratory anesthesia machines, and Huitong high-frequency electrocautery units. Since the laboratory’s establishment, nearly... has been invested. 2000 With the completion of multiple batches of trials, the laboratory has rapidly enhanced its national and international reputation and influence, solidifying its position as a domestic leader in preclinical large-animal studies for medical devices.
As an important intermediate link in the transformation of innovative medical devices from the innovation chain to the industrial chain, medical device safety evaluation research bridges the interaction and integration between the innovation chain and the industrial chain in the life sciences sector under the Qin Chuang Yuan initiative. This research holds significant value for the development of the province’s life sciences industry.
Guo Rui Xinchuang at 2021 Year 03 The license for the use of laboratory animals, issued by the Shaanxi Provincial Department of Science and Technology, makes us the only entity in our province to comply with... GLP Preclinical evaluation laboratory for medical devices in operation. At 2022 Year 07 The company has been awarded the National High-Tech Enterprise Certificate and currently holds 6 A computer software copyright.
Guorui Xin’s business scope:
1. For the National Medical Products Administration ( NMPA The Medical Device Technical Review Center provides preclinical animal studies and reports required for medical device registration.
2. For the United States FDA and the European Union ( OECD ) The certification provides preclinical animal studies and reports required for medical device registration.
3. Provide preclinical large-animal studies in the medical device R&D phase for innovative medical device companies, R&D institutions, and research institutes.
4. Provide technical training and promotion services for the clinical application of medical devices to innovative medical device companies, R&D institutions, and hospitals.
5. Establishment of various innovative animal models for basic research: experimental animal models for conditions such as myocardial infarction, heart failure, and fractures (including both large and small animals).
6. Evaluation reports for medical device products or projects serving government project support, investment fund consulting, and the initiation of R&D enterprise projects.
7. In vitro simulation platform testing and reporting for medical devices during the R&D and registration phases.
8. Provision of clinical trial protocols and advisory services based on physician teams and animal studies.
9. Training on medical knowledge related to medical device R&D and development of course materials.
10. Testing of medical devices based on ex vivo organs and training in new clinical technologies.
11. Joint application for national-level, provincial-level, and park-level medical device R&D innovation projects.
12. Industrialization services for doctors’ innovative designs and patent commercialization.
13. Report on Product R&D Evaluation and Improvement Optimization Based on Large Animal Studies.
Related News
Contact phone number
Ms. Li:+86 15760970681
Mr. Su:+86 19991001701
Landline:+86-29-33656828
Company Address
4th Floor, Unit C. Building 9. Small and Medium-sized
Enterprise Park, Airport Industrial Zone Airport New Ciy,Xixian New Area, Shaanxi Province
©2026 Xixian New Area Guorui Yinuo Drug Safety Evaluation and Research Co., Ltd.
WhatsApp：8613940397353
Email：hr-xian@grglp.com
Landline：862933656828
Mr. Su：8619991001701
Ms. Li：8615760970681